Monocytes from patients with sickle cell disease (SCD) are in an activated state.
Introduction
The clinical manifestations of sickle cell disease (SCD) include chronic hemolytic anemia, frequent infections and recurrent episodes of painful crises [1] [2] [3] [4] [5] [6] [7] . Vascular
For personal use only. on . by guest www.bloodjournal.org From 3 occlusion leading to episodes of painful crises and damage to various end organs is the major cause of morbidity and mortality in SCD 1, 3, 6, 8 . Hebbel and coworkers have shown that the extent of adherence of SS RBC to cultured endothelial cells appears to parallel the clinical severity of vaso-occlusive events in SCD 9 . However, SCD patients with an identical defect in their -globin genes show wide variability in the frequency and severity of vasoocclusive crises, and can remain asymptomatic for prolonged periods 2 . This could be due to the epistatic effects of co-inherited genes such as -globin andglobin [10] [11] [12] [13] , both of which have been shown to alter disease severity 13, 14 . However, the effects of and globin gene expression are not always predictable, suggesting that there must be factors other than those directly related to the RBC in the pathophysiology of vasoocclusion in SCD.
Clinically, it has been noted that leukocytosis is associated with increased frequency of vaso-occlusive crisis (VOC) 15, 16 . Moreover, a chronically elevated white cell count is a clear indicator of mortality 17 , frequency of acute chest syndrome 8, 18 and development of stroke 19, 20 in SCD. Since polymorphonuclear neutrophils (PMN) and monocytes are activated during infection and inflammation 15, 21 , we hypothesize they may play a role in the initiation and/or potentiation of vaso-occlusive episodes. Treatment of individuals with SCD with hydroxyurea causes a decrease in white blood cell count and a decrease in myeloperoxidase activity, indicating that reduced leukocytosis and leukocyte activation results in improvement in the incidence of vasoocclusive crises [22] [23] [24] . A recent study 25 shows that monocytes in SCD patients are in an activated state as they express more IL-1 and TNF-compared to normal monocytes. Furthermore, mononuclear cells from SCD patients can activate cultured endothelial cells, as judged by the increased expression of cell adhesion molecules and tissue factor in endothelial cells 25 . However, the mechanism by which monocytes in SCD patients become activated is relatively not understood.
In the preceding paper, we show that plasma levels of PlGF are higher in SCD patients compared to normal controls and they correlate with disease severity. The data also suggest that the higher levels of PlGF present in patients with SCD may be due to
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We have also shown that PlGF activates mononuclear cells (MNCs) resulting in increased gene expression of cytokines (TNF-, IL-1 ) and chemokines (MCP-1, IL-8 and MIP-1 ).
The present study shows that PlGF activated the monocyte fraction of the MNCs. We have examined the cellular signaling mechanism by which PlGF interaction with peripheral blood monocytes (PBM) and THP-1 monocytes results in increased expression of proinflammatory cytochemokines. We show that interaction of PlGF with Flt-1 receptor on monocytes caused downstream activation of PI3 kinase/AKT and ERK-1/2 pathways, which increased expression of aforementioned inflammatory cytokines and chemokines. We also show that PlGF induced activation of Src kinase, PI3 kinase/AKT and MAP kinase in monocytes promotes chemotaxis of monocytes. . Briefly, ten volumes of blood sample (30 mL) were mixed with one volume (3 mL) of a solution composed of 6% Dextran 500 in 0.9% NaCl. The tube was allowed to stand at room temperature for 45 minutes, which resulted in the sedimentation of erythrocytes. The leukocyte-rich plasma was harvested, layered over Nyco-prep media, density 1.068 g/mL (Accurate Chemical and Scientific Corporation, Westbury, NY) at a ratio of 2:1, and centrifuged at 600 g for 15 minutes. The monocyte fraction was further purified according to manufacturer's instructions. Finally, these cells were allowed to adhere for 1-2 hr in a 60 mm petri dish in the tissue culture incubator. By this procedure nonadherent lymphocytes were removed. Monocytes isolated by this procedure had purity in the range of ~90 % as assessed by labeling with MO2-FITC antibody (Coulter Diagnostics, Hialeah, FL) followed by FACscan analysis as previously described 26 with a yield of 55-75%.
Materials and Methods

Materials
Cell culture. THP-1, a promonocytic cell line was obtained from the American Type Culture Association (ATCC; Manassas, VA). Cells were cultured in RPMI-1640 medium containing 10% heat inactivated fetal bovine serum.
RNase protection assay. THP -1 monocytes were treated with PlGF for various time periods and total RNA was isolated from cultured cells with TriZOL reagent (Life Technologies). Assays were performed with a custom made Riboquant Multi-probe RNase protection assay system (Pharmingen). In brief, the isolated RNA (10 µg) was hybridized with 32 P labeled probes overnight at 56°C followed by RNase digestion according to manufacturer's instructions. GAPDH was used as an internal control. After digestion, the protected fragments were resolved on a 5% denaturing polyacrylamide gel, transferred to Whatman filter paper 3, which was dried and later exposed to X-ray film. The intensity of bands corresponding to TNF-, MIP-1 , IL-1 , MCP-1, IL-8 and GAPDH mRNA were analyzed using a gel documentation system. Values are 
Results
Expression of cytokines and chemokines in monocytes in normal and SS
patients.
Previous studies have shown that both polymorphonuclear neutrophils (PMN) 21 and monocytes 28 
Role of placenta growth factor in activation of monocytes
These studies indicated that monocytes in SCD were in activated state in vivo, generating cytokines and chemokines. We have also shown that PlGF, a factor produced by erythroid cells was responsible for activation of the mononuclear cell fraction, composed of monocytes and lymphocytes. Furthermore, we show that plasma 
Effect of PlGF treatment on the expression of cytokines and chemokines by
THP -1 cells
As shown in Figure 4A , there was a dose dependent effect of PlGF (25-250 ng/mL) on the mRNA expression of cytokine and chemokines in THP-1 monocytes, with optimal effect at 250 ng/mL. This dose of PlGF was used in all experiments, unless otherwise indicated. We then measured if increased mRNA expression of cytokines and chemokines in THP-1 monocytes was due to increased stability of mRNA. Extremely 
PlGF induced activation of ERK-1/2 in THP-1 cells
Previous studies have shown that monocytes express Flt-1 (VEGFR-1) but not Flk-1 (VEGFR-2) receptor 35 . We examined whether PlGF phosphorylated ERKs and required signaling thru Flt-1. RT-PCR analysis of THP-1 monocytes revealed the presence of Flt-1 mRNA but not flk-1 mRNA (data not shown). As shown in Figure 10A , treatment of THP-1 monocytes with PlGF (250 ng/mL) increased the phosphorylation of both ERK-1 (p44) and ERK-2 (p42). The peak phosphorylation of ERK-1/ -2 was observed at 3 minutes and declined thereafter. Moreover, antibody to Flt-1 inhibited PlGF-induced phosphorylation of ERK-1 and ERK-2 by 100% and 75%, respectively ( Figure 10A These above results were then confirmed in peripheral blood monocytes. As shown in Figure 10B , PlGF-induced phosphorylation of ERK at 5 minutes (optimal phosphorylation) was attenuated by both PI3 kinase and MEK inhibitors. Taken together, these findings indicate that activation of Flt-1 receptor, phospholipase C, and PI3 kinase/AKT by PlGF is required for activation of ERK in monocytes.
Effect of over expression of dominant negative isoforms of PI3 kinase and AKT on PlGF induced phosphorylation of ERK.
To specifically address the role of PI3 kinase/AKT in PlGF-induced modulation of ERK phosphorylation, we over expressed a dominant negative AKT (DNAKT) and a dominant negative PI3 kinase p85 subunit (DNM-p85). As shown in Figure 11 
Chemotactic response of THP-1 monocytes to PlGF
We determined whether PlGF increased monocyte chemotaxis. As shown in Figure   12A , PlGF caused a dose-dependent increase in the migration of monocytes. To determine whether the migration of THP-1 monocytes required a PlGF gradient we performed a checkerboard analysis. As shown in Table 1 , the maximal increase in the migration of monocyte occurred in response to a positive concentration gradient between the two compartments of the Boyden chamber, which decreased as the difference in the concentration of PlGF between lower and upper compartments declined. These results indicate that the response of THP-1 monocytes to PlGF was a result of chemotaxis and not of chemokinesis, as has been observed with VEGF induced chemotaxis of monocytes 37 . It is pertinent to note that MCP-1 (100 ng/mL), a positive control in these experiments, induced chemotaxis of THP-1 monocytes to a level slightly lower than PlGF alone (Figure 12 B) .
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Effect of pharmacological inhibitors on PlGF induced THP-1 monocyte chemotaxis
We determined whether pharmacological inhibitors of PlGF signaling also resulted in attenuation of monocyte chemotaxis. As shown in Figure 12B 
Discussion
Patients with sickle cell disease have abnormally high base-line leukocyte count, which is also observed in sickle transgenic mice 39, 40 . Moreover, it has been observed that the base line count of leukocytes is a very strong independent risk factor for severity of disease 40 . The abnormally high levels of leukocytes above the base line reflects ongoing chronic inflammation at steady state. Recent studies show that monocytes isolated from SCD blood are in the activated state 25 . Furthermore increased levels of IL-1 and TNF- 41, 42 , and IL-8 43 have been reported in sera from patients with SCD.
However, the nature of stimuli, which cause monocyte activation in SCD, is not known.
A recent study shows that erythroid cells, but not other hematopoietic cells express both vascular endothelial growth factor-A (VEGF-A) and placenta growth factor (PlGF) 44 . We 40 . We suggest that due to increased erythropoiesis in SCD, one finds increased levels of PlGF, which may act as a trigger on monocytes to produce cytochemokines, resulting in inflammatory response.
In Transfected cells were treated with PlGF for 3 minutes. Cell lysates were probed with antibody to ERKs as described in Figure 10 . The data is representative of three experiments. 
